Cannatrek Will Supply Cannabis to Project Twenty21

The Australian cannabis company Cannatrek has announced it will supply medicinal cannabis products to LYPHE Group in order to support Project TWENTY21 – Europe's first and largest national medicinal cannabis registry.

Australian seed-to-patient medicinal cannabis producer Cannatrek today announced it will supply medicinal cannabis products to LYPHE Group in support of Project TWENTY21, Europe's first and largest national medical cannabis registry.

Project TWENTY21 is both an effort to improve patient access to medicinal cannabis products as well as a research project. The project will provide medical cannabis to 20,000 patients around the UK, who suffer from a variety of conditions and diagnoses, including anxiety, chronic pain, epilepsy, PTSD and more.

In addition to supplying cannabis, Project TWENTY21 will be collating evidence regarding the efficacy of the medicinal cannabis products it supplies. Project TWENTY21 aims to recruit up to 20,000 patients by the end of this year, which would make it the largest medical cannabis project in Europe.

Following a supply agreement with LYPHE Group secured in October last year, Cannatrek will now also be supplying medicinal cannabis flowers for the TWENTY21 project via LYPHE Group.

Tommy Huppert, Cannatrek CEO, said Cannatrek's products will be among the first used in the trial, and will be the first locally produced Australian grown herbal cannabis ever exported into the UK.

"For us, it opens up international trade pathways in what is still a nascent industry," he said. "Project TWENTY21, with 20,000 patients, represents a very big study and will produce lots of valuable data for Cannatrek and for the industry. Crucially for us, Cannatrek is an important part of the supply chain for this study. Supply chains are being created very rapidly worldwide and we want to be front and centre of them."

Chris Ashton, Chief Commercial Officer at LYPHE Group, said: "Project T21 is an incredibly important study in the UK and presents a great opportunity for the industry to demonstrate with valuable data the effectiveness and safety of using medical cannabis. It's great to have the support of Cannatrek, as a valued supplier to LYPHE Group, recognizing and supporting the study and helping so many patients. This will go a long way to ensuring that we have a continuous and high-quality supply chain ensuring the continued success of the Project TWENTY21 study."

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.